Physician profile
Daniel L Arnold
NPI 1205838133
$3,207.06
in general payments reported to CMS, 2019-2025
30 companies · $38.98 in 2025
The $38.98 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $828 · 2020: $601 · 2021: $657 · 2022: $844 · 2023: $187 · 2024: $50.50 · 2025: $38.98.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $277.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $276.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $459.31 | 2019-2023 | Vraylar, Ubrelvy |
| Novo Nordisk INC | $375.42 | 2021-2023 | Wegovy |
| Astrazeneca Pharmaceuticals Lp | $365.52 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $340.66 | 2019-2022 | |
| Amarin Pharma, INC. | $228.57 | 2019-2023 | |
| Amgen INC. | $227.04 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $208.13 | 2019-2023 | |
| Glaxosmithkline, LLC. | $201.36 | 2020-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Pfizer INC. | $149.30 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.11 | 2020-2025 | Jardiance |
| Allergan, INC. | $64.74 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $61.82 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $47.86 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $47.86 | 2019-2020 | |
| Lilly USA, LLC | $44.33 | 2021-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $38.98 | 2021 | |
| Supernus Pharmaceuticals, INC. | $35.88 | 2021 | |
| Abbott Laboratories | $35.01 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.24 | 2019 | |
| Circassia INC. | $19.33 | 2019 | |
| Genentech USA, INC. | $18.73 | 2019 | |
| Eisai INC. | $18.56 | 2020 | |
| Almatica Pharma LLC | $16.78 | 2021 | |
| Esperion Therapeutics, INC. | $16.22 | 2021 | |
| Hologic Sales and Service, LLC | $15.99 | 2023 | Aptima |
| Takeda Pharmaceuticals U.S.A., INC. | $13.56 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $12.40 | 2022 | |
| Horizon Therapeutics Plc | $11.86 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $11.42 | 2021 | |
| Sanofi Pasteur INC. | $11.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Arnold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.